Spyre Therapeutics, Inc. (SYRE)
NASDAQ
Real-time Data
01:30 PM
Day's Range
105.0052 wk Range
14.51Overview - SYRE - Spyre Therapeutics, Inc.
Key Statistics
Valuation
Enterprise Value
8.40B
P/E (Trailing)
‪1.68‬
P/E (Forward)
‪-30.96‬
PEG Ratio
‪-0.05‬
Price / Book
‪9.83‬
EV / EBITDA
‪-36.61‬
Profitability
Profit Margin
‪0.00%‬
Operating Margin
‪0.00%‬
Return on Assets
‪-19.81%‬
Return on Equity
‪-22.98%‬
Ownership
Shares Outstanding
88.06M
Float
82.14M
Short % of Shares Outstanding
‪14.72%‬
Held by Insiders
‪5.73%‬
Held by Institutions
‪110.68%‬
Price stats
Beta
‪3.02‬
50-Day Avg
‪96.96‬
200-Day Avg
‪58.47‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
17 analysts
Average price target
‪$ 124.71‬Shariah Compliance
Report Date: Feb 18, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - SYRE - Spyre Therapeutics, Inc.
Peers - SYRE - Spyre Therapeutics, Inc.
Peer Comparison
Compared with companies in Biotechnology listed on NASDAQ.
- SYRENASDAQSpyre Therapeutics, Inc.9.45BMarket Cap+84.59%52-week change1.68P/E (Trailing)‪0.00%‬Profit Margin
- ARGXNASDAQargenx SE American Depositary Receipt62.93BMarket Cap+33.08%52-week change39.69P/E (Trailing)‪32.26%‬Profit Margin
- ALNYNASDAQAlnylam Pharmaceuticals Inc31.58BMarket Cap-87.93%52-week change40.23P/E (Trailing)‪16.12%‬Profit Margin
- BNTXNASDAQBioNTech SE28.34BMarket Cap+7.12%52-week change160.80P/E (Trailing)‪-63.63%‬Profit Margin
- ASNDNASDAQAscendis Pharma A/S16.61BMarket Cap+23.98%52-week change19.38P/E (Trailing)‪70.84%‬Profit Margin
- BBIONASDAQBridgeBio Pharma, Inc.15.84BMarket Cap+39.72%52-week change-21.44P/E (Trailing)‪-97.02%‬Profit Margin
- BMRNNASDAQBiomarin Pharmaceutical Inc.12.59BMarket Cap+11.71%52-week change180.27P/E (Trailing)‪2.14%‬Profit Margin
Profile Summary - SYRE - Spyre Therapeutics, Inc.
About
Spyre Therapeutics, Inc. is a clinical-stage biotechnology company developing next-generation antibodies engineered for prolonged activity in the body, formulated for delivery as monotherapies or combination therapies. These innovative antibodies target validated mechanisms to address inflammatory bowel disease (IBD)…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
